Ionis Pharmaceuticals, Inc.
Modulators of APOL1 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
Status:
Grant
Type:
Utility
Filling date:
21 May 2019
Issue date:
23 Feb 2021